Saag KG, et al. - For glucocorticoid-induced osteoporosis, researchers compared the efficacy of treatment with denosumab 60 mg subcutaneously once every 6 months vs treatment with risedronate 5 mg orally once daily. In addition, they determined safety of both through month 24. Men and women ≥18 years old who took ≥7.5 mg daily prednisone or equivalent for <3 months (glucocorticoid-initiating) or for ≥3 months (glucocorticoid-continuing) prior to screening were enrolled in this phase 3 study. The study was completed by 590 (74.2%) of 795 patients; in the glucocorticoid-initiating group, 109 of 145 patients treated with denosumab and 117 of 145 patients treated with risedronate completed, and in the glucocorticoid-continuing group, 186 of 253 patients treated with denosumab and 178 of 252 patients treated with risedronate completed. For increases in spine and hip BMD through month 24 the superiority of denosumab vs risedronate was confirmed. The treatment groups had a comparable safety profile. Findings suggest that for glucocorticoid-treated patients, denosumab is a new osteoporosis treatment option.